Topic:

Emerging Markets

Latest Headlines

Latest Headlines

Teva 'likely' violated FCPA, local laws in Russia, Latin America and elsewhere

Teva has been investigating for some time whether its business practices abroad have breached the Foreign Corrupt Practices Act (FCPA) and/or local laws. And now, it says it's "likely" they have.

Tear up the rules and start again, Lancet panel says to India on drug safety

SINGAPORE-- One of the world's most prestigious medical journals called for India to abandon its current proposal to change the way it regulates drugs and come up with a new plan.

Sanofi sees major China boost from heart, diabetes drugs, exec says

SINGAPORE-- China sales of Sanofi's heart and diabetes drugs contributed heavily to sales growth in the country last year, with the market witnessing twice the growth of the rest of the world combined.

India's Aurobindo Pharma eyes major earnings boost if U.S. FDA comes through on applications

SINGAPORE-- Aurobindo Pharma's U.S. unit, AuroMedics Pharma USA, says that if the U.S. FDA manages to speed up its approval process for generic drugs in the coming fiscal year, its earnings could shoot up by half.

Investors set sail toward China's rapidly growing device market

Amid rapid growth in China's medical device sector, investors are looking to cash in on the market with a string of M&A deals.

Cipla to build a manufacturing plant in Morocco with local partners

Cipla, which has been building beachheads and production capacity in hot spots where most Western drugmakers are loath to go, will now create a joint venture in Morocco and build a drug manufacturing facility there.

Competition to J&J's Remicade looms in U.S. as biosimilar conquers new markets

South Korea's Celltrion will start sales of Remsima, its biosimilar of Johnson & Johnson's Remicade (infliximab) in a dozen European countries in February, according to Joon Seok Kim of Celltrion Public Relations on Tuesday.

Cellular Biomedicine inks CAR-T deal with Chinese General Hospital

SINGAPORE-- Cellular Biomedicine Group has bought chimeric antigen receptor T cell therapies from the Chinese PLA General Hospital in a deal valued at RMB12 million ($1.9 million) to be paid in three installments.

Strides Arcolab, Shasun merger in India faces shareholder test

SINGAPORE-- A proposed $200 million merger between India's Strides Arcolab and Shasun Pharmaceuticals is about to be tested by Shasun's shareholders.

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets

FiercePharma brings you notes on the Asian and emerging markets operations of major drug companies from fourth-quarter earnings calls to explain what C-suite executives are focused on.